AstraZeneca PLC Files 9M and Q3 2025 Results

TL;DR

AZN dropped Q3 results, check the 6-K for deets.

AI Summary

AstraZeneca PLC filed a Form 6-K on November 6, 2025, reporting its 9-month and Q3 2025 results. The filing is a report of a foreign issuer and indicates that AstraZeneca files annual reports under Form 20-F. The company's address is in Cambridge, United Kingdom.

Why It Matters

This filing provides investors with AstraZeneca's latest financial performance for the first nine months and third quarter of 2025, crucial for assessing the company's ongoing health and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial results filing and does not contain new or unusual risk factors.

Key Players & Entities

• AstraZeneca PLC (company) — Filer of the report
• 001-11960 (company) — SEC File Number
• 20251106 (date) — Filing date
• November 2025 (date) — Reporting period
• 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom (company) — Company address

FAQ

From the Filing

0001654954-25-012630.txt : 20251106 0001654954-25-012630.hdr.sgml : 20251106 20251106073627 ACCESSION NUMBER: 0001654954-25-012630 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20251106 FILED AS OF DATE: 20251106 DATE AS OF CHANGE: 20251106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251456192 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a4030g.htm 9M AND Q3 2025 RESULTS a4030g FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of November 2025    Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________             AstraZeneca PLC   INDEX TO EXHIBITS     1. 9M and Q3 2025 results       6 November 2025     AstraZeneca results: 9M and Q3 2025   Continued strong commercial performance and unprecedented pipeline delivery in the year to date   Revenue and EPS summary     9M 2025         % Change Q3 2025         % Change   $m  Actual  CER 1 $m  Actual  CER   - Product Sales 41,035  9  9  14,365  11  9   - Alliance Revenue 2,108  41  41  815  46  44  Product Revenue 2 43,143  10  11  15,180  12  11  Collaboration Revenue 93  (14) (15) 11  (81) (82) Total Revenue 43,236  10  11  15,191  12  10  Reported EPS ($) 5.10  43  42  1.64  77  70  Core 3   EPS ($) 7.04  15  15  2.38  14  12    Key performance elements for 9M 2025   (Growth numbers at constant exchange rates)   ● Total Revenue up 11% to $43,236m, driven by growth in all Therapy Areas, including 16% growth in Oncology and 13% growth in R&I ● Growth in Total Revenue across all major geographic regions ● Core Operating profit increased 13% ● Core EPS increased 15% to $7.04 ● 16 positive Phase III readouts and 31 approvals in major regions   Pascal Soriot, Chief Executive Officer, AstraZeneca, said:   "